Verseon to Present Preclinical Data on Novel Anticancer Candidates for Use against Multidrug Resistant Cancers
October 31 2017 - 8:22AM
Business Wire
Verseon will present preclinical data on its novel anticancer
drug candidates, which have shown promising results in preliminary
testing against tumor cell lines resistant to major chemotherapy
agents. The results will be shown at the BIO-Europe conference held
in Berlin from November 6–8, 2017.
Cancer still remains a primary concern with almost 1.7 million
people in the US newly diagnosed with some form of cancer in 2016.
Currently, chemotherapy is essential to the treatment of most
cancers. However, tumors in many patients become resistant to
chemotherapy agents over time, limiting the effectiveness of
available drugs.
Dr. Anirban Datta, Verseon’s Director of Discovery Biology, will
present the first preclinical results on a new class of anticancer
agents, which are potent against a range of cancer cell lines in
cell-based assays. In particular, he will highlight the
effectiveness of these new drug candidates against cancer cell
lines resistant to established chemotherapy agents.
“We are really excited about these results as they show that our
novel chemotherapy agents are largely unaffected by mechanisms of
multidrug resistance. This fills an important need for the
treatment of many cancers, especially for patients with recurrent
solid tumors,” said Dr. Datta.
Verseon uses its innovative computer-driven drug discovery
platform to generate new drug candidates for a variety of
indications. This platform provides access to many more drug-like
molecules than are available to conventional pharmaceutical
companies. Verseon currently has active programs in
anticoagulation, diabetic macular edema, hereditary angioedema, and
oncology.
Details of the presentation are as follows:
Date: Tuesday, November 7, 2017
Time: 5:15 PM
Location: CityCube Berlin, Room M3 on Level 3
About Verseon
Verseon Corporation (www.verseon.com, AIM: VSN) is a
technology-based pharmaceutical company that employs its
proprietary, computational drug discovery platform to develop novel
therapeutics that are unlikely to be found using conventional
methods. The Company is applying its platform to a growing drug
pipeline and currently has four active drug programs in the areas
of anticoagulation, diabetic macular edema, hereditary angioedema,
and oncology.
www.verseon.com
- Ends -
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171031005802/en/
Vane Percy & RobertsSimon Vane Percy+44 (0) 1737 821 890
Verseon (LSE:VSN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Verseon (LSE:VSN)
Historical Stock Chart
From Apr 2023 to Apr 2024